Tag: #Rituximab
-
Rituximab in Adult Minimal Change DiseaseMechanisms and Clinical Research Progress
Introduction:Minimal Change Disease (MCD) is a significant cause of nephrotic syndrome in adults, often leading to severe proteinuria, edema, and hypoalbuminemia. While corticosteroids remain the first-line treatment, Rituximab (RTX), a monoclonal antibody targeting CD20, has emerged as a promising therapy for refractory cases. This article explores the mechanisms of RTX and its clinical applications in…
-
Rituximab in Adult Minimal Change Disease: A Breakthrough in Nephrotic Syndrome Treatment
Introduction Minimal Change Disease (MCD) is a prevalent form of nephrotic syndrome, particularly in children, but also affects adults. The exact pathogenesis of MCD remains unclear, but emerging research highlights the roles of both T cells and B cells in its development. Rituximab (RTX), a monoclonal antibody targeting CD20, has gained attention as a promising…
-
Posterior Reversible Leukoencephalopathy Syndrome After Rituximab A Rare but Severe Complication
Introduction: Posterior Reversible Encephalopathy Syndrome (PRES) is a neurological disorder presenting with seizures, headaches, visual disturbances, and altered consciousness. It has been linked to conditions like uncontrolled hypertension (HTN), thrombotic thrombocytopenic purpura (TTP), and immunosuppressive treatments. While PRES typically occurs after the first dose of Rituximab, this case highlights its occurrence after a second dose.…
Heighten Science Publications Inc. 